New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
J Frau, G Coghe, L Lorefice, G Fenu… - … disease and treatment, 2018 - Taylor & Francis
Multiple Sclerosis (MS) is an inflammatory and neurodegenerative disease of the central
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population
H Coban, S Germaine, I Dimaandal, N Haberli… - Multiple Sclerosis and …, 2021 - Elsevier
Background Ocrelizumab (OCR) is a humanized monoclonal antibody directed against
CD20 positive B-lymphocytes. It was approved for use in 2017 by the US Food and Drug …
CD20 positive B-lymphocytes. It was approved for use in 2017 by the US Food and Drug …
Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis
Background: Ongoing safety reporting is crucial to understanding the long-term benefit–risk
profile of ocrelizumab in patients with multiple sclerosis (MS). The safety and efficacy of …
profile of ocrelizumab in patients with multiple sclerosis (MS). The safety and efficacy of …
Real‐world evaluation of ocrelizumab in multiple sclerosis: A systematic review
X Montalban, PM Matthews, A Simpson… - Annals of clinical …, 2023 - Wiley Online Library
Across its clinical development program, ocrelizumab demonstrated efficacy in improving
clinical outcomes in multiple sclerosis, including annualized relapse rates and confirmed …
clinical outcomes in multiple sclerosis, including annualized relapse rates and confirmed …
Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients
V Prockl, FT Nickel, KS Utz, K Fröhlich… - Journal of the …, 2020 - Elsevier
Background Pivotal trials showed good clinical efficiency of the monoclonal antibody
ocrelizumab while being well tolerated and manageable in multiple sclerosis (MS) …
ocrelizumab while being well tolerated and manageable in multiple sclerosis (MS) …
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
Objective Ocrelizumab inhibits relapsing multiple sclerosis when administered every six
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …
Immunomodulatory effects of ocrelizumab and candidate biomarkers for monitoring treatment response in multiple sclerosis
G Abbadessa, G Miele, E Maida… - Multiple Sclerosis …, 2023 - journals.sagepub.com
Ocrelizumab is a humanized monoclonal antibody designed to bind to the CD20 molecule,
resulting in a rapid depletion of B-cells; however, it has been shown that lymphocyte …
resulting in a rapid depletion of B-cells; however, it has been shown that lymphocyte …
Ocrelizumab: first global approval
JE Frampton - Drugs, 2017 - Springer
Ocrelizumab (Ocrevus™) is a humanised anti-CD20 monoclonal antibody that has been
developed by Genentech, Inc.(a subsidiary of Roche) for the treatment of multiple sclerosis …
developed by Genentech, Inc.(a subsidiary of Roche) for the treatment of multiple sclerosis …
Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts …
P Dirks, V Zingler, J Leemhuis, H Berthold… - BMC neurology, 2020 - Springer
Background Multiple sclerosis (MS) is a chronic disease that requires lifelong treatment. A
highly effective drug not only for relapsing but also for progressive forms of MS with a …
highly effective drug not only for relapsing but also for progressive forms of MS with a …